Integrative Clinical and Practical Hematology
Vol. 2 No. 1 (2019)
Review Article

Acute Promyelocytic Leukemia: Pathophysiology, Laboratory and Clinical Characteristics, Treatment and Minimal Residual Disease- A Literature Review

PDF
  • Bruna Amorin,
  • Helena Schirmer,
  • Vanessa Valim,
  • Annelise Pezzi,
  • Ianaê Wilke,
  • Maria Aperecida Lima da Silva,
  • Filipe Sehn,
  • Alice Dahmer,
  • Lucia Silla,
  • Bruna Zambonato,
  • Leticia Baggio
Bruna Amorin
Especialização em Análises Clínicas da Universidade FEEVALE, Novo Hamburgo, Rio Grande do Sul, Brasil
Helena Schirmer
Especialização em Análises Clínicas da Universidade FEEVALE, Novo Hamburgo, Rio Grande do Sul, Brasil
Vanessa Valim
Centro de Terapia e Tecnologia Celular, Hospital de Clinicas de Porto Alegre, HCPA, Rio Grande do Sul, Brasil
Annelise Pezzi
Centro de Terapia e Tecnologia Celular, Hospital de Clinicas de Porto Alegre, HCPA, Rio Grande do Sul, Brasil
Leticia Baggio
Centro de Terapia e Tecnologia Celular, Hospital de Clinicas de Porto Alegre, HCPA, Rio Grande do Sul, Brasil
Published July 1, 2019
Keywords
  • Acute promyelocytic leukemia,
  • PML-RARα,
  • Minimal residual disease

Copyright (c) 2019 Amorin

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Acute Promyelocytic Leukemia (APL) is a subtype of acute leukemia characterized by a predominance of cells with characteristic morphology, by t(15;17) and coagulopathy. It is designated as M3 by FAB classification and as APL with t(15;17) or PML/RARα rearrangement by the World Health Organization. Unlike other subtypes of acute myeloid leukemia (AML), APL occurs most often in young adults and has a stable incidence between 20 to 59 years old. This disease, which used to be highly mortal, has become a curable disease since the establishment of standard treatment with all-trans retinoic acid and anthracyclines in the 90s. Therefore, this study aimed to review the pathophysiology, diagnosis, prognosis, treatment, and monitoring response to treatment of APL.

PDF